Navigation Links
Challenge Spreadable Butter Now Features Martek's life'sDHA(TM)
Date:2/4/2008

COLUMBIA, Md., Feb. 4 /PRNewswire-FirstCall/ -- Martek Biosciences (Nasdaq: MATK) announced today that life'sDHA(TM), its patented, vegetarian form of DHA omega-3 for brain, eye and heart health, is now available to consumers in the new 15 oz. Challenge Spreadable Butter from Challenge Dairy Products, Inc. Challenge 15 oz. Spreadable Butter can be found in supermarkets throughout the Northwest.

Founded in 1911, Challenge Dairy Products, Inc., is a cooperative association responsible for the marketing and distribution of dairy products produced from over 600 large, family-owned dairies. Challenge Butter is the largest selling brand in the Western U.S. Challenge also markets Danish Creamery Butter, a strong brand in Southern California and the San Joaquin Valley.

"Challenge Spreadable Butter illustrates how Martek's life'sDHA can be added to food products that are already staples in many households," said Angela Tsetsis, vice president, commercial for Martek. "We're pleased to be working with Challenge Dairy to offer consumers healthier choices in products they use every day."

About DHA

DHA (docosahexaenoic acid) omega-3 is a long-chain omega-3 fatty acid that serves as a primary building block for the brain and the eyes and supports brain, eye and cardiovascular health throughout life. There is a large and growing body of scientific evidence demonstrating that people of all ages, from infants to aging adults, benefit from an adequate supply of DHA omega-3 in their diets. Several recent scientific reviews have noted the importance of DHA omega-3 in proper brain and eye development and function, and there are large clinical studies underway to evaluate its role in decreasing the prevalence of certain neurological disorders.

About life'sDHA

Fish are often thought to be the only source of DHA omega-3. However, life'sDHA offers a trusted, vegetarian form of DHA that contains no oceanic pollutants and toxins. Fish are good sources of DHA because of the DHA-rich microalgae in their foodchain; life'sDHA is derived from microalgae and produced in an FDA-inspected facility from start to finish using a sustainable source that does not deplete ocean resources. life'sDHA is found in numerous foods, beverage and supplements for people of all ages. It is also the only source of DHA used in U.S. infant formula and is available in more than 90 percent of the formulas on the U.S. market.

Martek Biosciences Corporation

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The company produces life'sDHA(TM), a sustainable and vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, beverages, infant formula, and supplements. The company also produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, from a sustainable, vegetarian source, for use in infant formula. For more information on Martek Biosciences Corporation, visit http://www.martek.com. For a complete listing of life'sDHA products, visit http://www.lifesdha.com.

Forward-Looking Statements

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2007 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

Contact:

Cassie France-Kelly

Consumer and Trade Media

Martek Biosciences

(443) 542-2116

media@martek.com

Kyle Stults

Investor Relations

Martek Biosciences

(410) 740-0081

investors@martek.com


'/>"/>
SOURCE Martek Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. White Paper Details Infection Control Challenges Hospitals Must Address During Construction
2. Beyond DTC: Pharma Industry Faces New Challenges, Competition, Strategies for Market Dominance
3. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
4. Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
5. Triage study challenges notions of emergency medical response to disaster
6. Free White Paper Addresses Challenges of New FDA Regulations Awaiting Combo Product Manufacturers
7. Barr Confirms Patent Challenge of Focalin(R) XR
8. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
9. Communicating Clinical Trial Data: Timing Remains Key Challenge for Marketing Teams
10. Sol-gel inks produce complex shapes with nanoscale features
11. Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... PMG Research is pleased ... conference presented by The Conference Forum in Boston on April 3-4, 2017. The CTC ... improved clinical trial outcomes and bring them closer to the patient. Clinical Trial Collaborations ...
(Date:3/27/2017)... , March 27, 2017  Trovagene, Inc. (NASDAQ: ... its Chief Executive Officer, Bill Welch , will ... 4, 2017 at 9:00 AM EDT at the Essex ...  Bill Welch, and Chief Scientific Officer, Mark Erlander ... investors during the conference.   The presentation will ...
(Date:3/27/2017)... , March 27, 2017 Neurotrope, ... novel therapies for neurodegenerative diseases, including Alzheimer,s disease, ... its application to list the Company,s common stock ... by The NASDAQ Stock Market, a unit of ... listing, Neurotrope will ring the Opening Bell at the ...
(Date:3/24/2017)... ROCKVILLE, Md. , March 24, 2017 ... Biotech Venture Fund (MBVF), today announced positive results of ... the standard drug therapy regimen in patients with multidrug-resistant ... drug discovered by scientists at Sequella, Inc. ( ... Health. A total of 140 patients ...
Breaking Biology Technology:
(Date:2/28/2017)... Germany , February 28, 2017 News ... ... Amsterdam from 14 to 16 March, Materna ... destination, and show how seamless travel is a real benefit for ... has added biometrics to their passenger touch point solutions to take ...
(Date:2/27/2017)...   Strategic Cyber Ventures , the industry,s first ... $3.5 million investment in  Polarity , the first commercial ... DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran and ... series A round of funding. This new funding will ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader ... its elite iris biometric solution on the latest ... LTE at Mobile World Congress 2017 (February ... Booth in Hall 3, Stand 3E10. ... Qualcomm Haven™ security platform—a combination of hardware, ...
Breaking Biology News(10 mins):